Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$91.42 USD

91.42
364,986

-0.16 (-0.18%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services

by Zacks Equity Research

Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.

Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches

by Zacks Equity Research

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?

by Zacks Equity Research

Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.

Thermo Fisher (TMO) Inks New Partnership for myeloMATCH Trial

by Zacks Equity Research

Thermo Fisher (TMO) announces a partnership with the National Cancer Institute for the myeloMATCH precision medicine umbrella trial to fuel research regarding new treatments for AML and MDS.

Hyperfine (HYPR) Inks New Partnerships to Expand in Europe

by Zacks Equity Research

Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.

STERIS (STE) AST Business Expands, New Offerings Aid Growth

by Zacks Equity Research

STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

Shaun Pruitt headshot

Top Medical Stocks to Buy for Growth & Performance

by Shaun Pruitt

The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

by Zacks Equity Research

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Wall Street Analysts Think Haemonetics (HAE) Could Surge 33.2%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 33.2% upside potential for Haemonetics (HAE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

by Zacks Equity Research

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.

Thermo Fisher (TMO) to Open New NanoPort Facility in Taiwan

by Zacks Equity Research

Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region???s semiconductor manufacturing hub.

Nilanjan Choudhury headshot

5 Well-Positioned Relative Price Strength Stocks to Buy Now

by Nilanjan Choudhury

NEP, TREE, HAE, CTRA and WSM are five stocks with explosive relative price strength.

QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership

by Zacks Equity Research

QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.

Reasons to Retain Baxter International (BAX) in Your Portfolio Now

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Haemonetics (HAE) Loses -5.16% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Zacks Industry Outlook Highlights Boston Scientific, ResMed, Lantheus and Haemonetics

by Zacks Equity Research

Boston Scientific, ResMed, Lantheus and Haemonetics are part of the Zacks Industry Outlook article.

Haemonetics (HAE) Expands VASCADE Line With New Limited Launch

by Zacks Equity Research

Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy From a Recovering Industry

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.

HAE vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HAE vs. BSX: Which Stock Is the Better Value Option?

Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks.com featured highlights include Skechers, Walmart, Haemonetics, AZZ and BOK Financial

by Zacks Equity Research

Skechers, Walmart, Haemonetics, AZZ and BOK Financial have been highlighted in this Screen of The Week article.

Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation

by Zacks Equity Research

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

McKesson (MCK) Gains 26% YTD: What's Driving the Rally?

by Zacks Equity Research

McKesson's (MCK) shares have risen year to date on the back of strong fundamentals. Rising volumes of prescription and specialty drugs boost the top line.

DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?

by Zacks Equity Research

DaVita's (DVA) shares have risen year to date on the back of strong performance and the acquisition of dialysis centers.